6.66

3.20% -0.22

After Hours: 6.75 0.09 +1.35%

Karyopharm Therapeutics Inc (KPTI)

Overview News Price History Option Chain Financials Discussions Forecast

Karyopharm Therapeutics Inc stock is traded at $6.66, with a volume of 39,963. It is down -3.20% in the last 24 hours and up +5.55% over the past month. Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Previous Close:

$6.88

Open:

$6.77

24h Volume:

39,963

Relative Volume:

0.25

Market Cap:

$57.75M

Revenue:

$137.27M

Net Income/Loss:

$-123.57M

P/E Ratio:

-0.6082

EPS:

-10.95

Net Cash Flow:

$-102.89M

1W Performance:

+16.23%

1M Performance:

+5.55%

6M Performance:

+18.93%

1Y Performance:

-36.30%

1-Day Range:

$6.66

$7.18

1-Week Range:

$5.32

$7.90

52-Week Range:

$3.51

$16.95

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name

Karyopharm Therapeutics Inc

Sector

Healthcare (1143)

Industry

Biotechnology (642)

Phone

617-658-0600

Address

85 WELLS AVENUE, NEWTON, MA

Employee

279

Twitter

@Karyopharm

Next Earnings Date

2024-11-05

Latest SEC Filings

KPTI's Discussions on Twitter

Compare KPTI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KPTI Karyopharm Therapeutics Inc	6.66	59.66M	137.27M	-123.57M	-102.89M	-10.95
VRTX Vertex Pharmaceuticals Inc	381.87	96.56B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	449.58	60.08B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	555.51	61.15B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	711.09	44.66B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	328.71	36.23B	3.81B	-644.79M	-669.77M	-6.24

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-16-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-11-25	Resumed	H.C. Wainwright	Buy
Jan-19-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-02-20	Initiated	Morgan Stanley	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-05-19	Reiterated	H.C. Wainwright	Buy
Jul-05-19	Reiterated	Robert W. Baird	Outperform
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral
Feb-28-19	Reiterated	BofA/Merrill	Underperform
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform
Jan-03-19	Upgrade	BofA/Merrill	Underperform → Neutral
Dec-03-18	Initiated	B. Riley FBR	Buy
Nov-09-18	Upgrade	Wedbush	Neutral → Outperform
May-24-18	Downgrade	Wedbush	Outperform → Neutral
Apr-02-18	Resumed	Leerink Partners	Outperform
Nov-15-17	Resumed	H.C. Wainwright	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-08-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Upgrade	Jefferies	Hold → Buy
Aug-18-16	Initiated	H.C. Wainwright	Buy
Jun-28-16	Initiated	Robert W. Baird	Outperform

View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

Sep 24, 2025

Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last? - Nasdaq

Sep 24, 2025

Sep 23, 2025

Smart tools for monitoring Karyopharm Therapeutics Inc.’s price actionWeekly Stock Recap & Weekly High Momentum Picks - newser.com

Sep 23, 2025

Karyopharm increases authorized shares, approves reverse split - MSN

Sep 23, 2025

Sep 22, 2025

Ideas Watch: Can Karyopharm Therapeutics Inc disrupt its industryMarket Sentiment Review & Weekly Top Gainers Alerts - خودرو بانک

Sep 22, 2025

Sep 21, 2025

Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) dropped from S&P Global BMI Index - MarketScreener

Sep 21, 2025

Sep 20, 2025

Market Overview: Is Karyopharm Therapeutics Incs ROIC above industry average2025 Stock Rankings & Capital Efficiency Focused Ideas - خودرو بانک

Sep 20, 2025

Sep 19, 2025

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $34.00 Consensus Price Target from Analysts - MarketBeat

Sep 19, 2025

Death Cross: Is Karyopharm Therapeutics Incs growth already priced inCEO Change & Fast Exit Strategy with Risk Control - khodrobank.com

Sep 19, 2025

Sep 17, 2025

Is Karyopharm Therapeutics Inc. stock entering bullish territoryJuly 2025 Drop Watch & Free Expert Verified Stock Movement Alerts - newser.com

Sep 17, 2025

Risk Check: Can Bread Financial Holdings Inc continue delivering strong returnsLayoff News & Free Accurate Trade Setup Notifications - خودرو بانک

Sep 17, 2025

Aug Rallies: Is Cartesian Growth Corporation Equity Warrant forming a double bottomEarnings Trend Report & Safe Entry Trade Signal Reports - khodrobank.com

Sep 17, 2025

Insider Buy: Will Karyopharm Therapeutics Inc. benefit from rate cuts2025 Key Highlights & Entry Point Confirmation Signals - خودرو بانک

Sep 17, 2025

Sep 16, 2025

Karyopharm CEO Paulson sells $8k in shares By Investing.com - Investing.com South Africa

Sep 16, 2025

Karyopharm therapeutics EVP Cheng sells $2089 in stock By Investing.com - Investing.com Canada

Sep 16, 2025

Aug Wrap: Is SLM Corporation part of any major indexWeekly Market Report & Low Risk Profit Maximizing Plans - خودرو بانک

Sep 16, 2025

Gap Down: Is Karyopharm Therapeutics Inc gaining market share2025 Investor Takeaways & Technical Pattern Based Signals - خودرو بانک

Sep 16, 2025

Volatility Watch: What are Karyopharm Therapeutics Inc.’s recent SEC filings showingQuarterly Profit Report & AI Based Trade Execution Alerts - خودرو بانک

Sep 16, 2025

Entry Recap: Will Karyopharm Therapeutics Inc. benefit from current market trends2025 Top Gainers & Stock Portfolio Risk Control - خودرو بانک

Sep 16, 2025

Sep 15, 2025

Wall Street Recap: Is Karyopharm Therapeutics Inc gaining market shareJuly 2025 Action & Fast Gain Stock Tips - خودرو بانک

Sep 15, 2025

Volume Report: What are Karyopharm Therapeutics Inc.’s recent SEC filings showingWeekly Trade Report & Reliable Trade Execution Plans - khodrobank.com

Sep 15, 2025

These biotechs are in the market for a buyer - The Business Journals

Sep 15, 2025

Income Plays: Will Karyopharm Therapeutics Inc outperform its industry peersTrade Analysis Summary & Short-Term Swing Trade Alerts - خودرو بانک

Sep 15, 2025

Sep 13, 2025